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Abstract 24 
A feature of mature Plasmodium falciparum parasitized red blood cells is their ability to bind 25 
surface molecules of the microvascular endothelium via the parasite-derived surface protein 26 
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). This ligand is associated 27 
with the cytoadherence pathology observed in severe malaria. As pRBC treated with effective 28 
anti-malarial drugs are still able to cytoadhere, there is therefore a need to find an adjunct 29 
treatment that can inhibit and reverse the adhesion process. One semi-synthetic, sulfated 30 
polysaccharide has been identified that is capable of inhibiting and reversing sequestration of 31 
pRBC on endothelial cells in vitro under physiological flow conditions. Furthermore, it exhibits 32 
low toxicity in the intrinsic (APTT assay) and extrinsic (PT assay) clotting pathways, as well as 33 
exhibiting minimal effects on cell (HUVEC) viability (MTT proliferation assay). These findings 34 
suggest that carbohydrate-based anti-adhesive candidates may provide potential leads for 35 
therapeutics for severe malaria. 36 
 37 
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Introduction 39 
An important characteristic of the pathogenesis of severe malaria (SM) results from the 40 
ability of parasitized red blood cells (pRBC) to sequester in the microvasculature, supported 41 
by post-mortem studies of cerebral malaria (CM) that indicate high levels of pRBC bound in 42 
brain microvessels [1, 2]. The involvement of sequestration in pathogenesis could be a result 43 
of microvasculature occlusion, and/or downstream effects caused by interactions between 44 
pRBC and the endothelium, including local inflammatory responses. [3]. 45 
The cytoadherence of pRBC to vascular endothelial cells occurs when PfEMP1, a 46 
parasite derived molecule present on the surface of pRBC, binds to several distinct adhesion 47 
molecules present on the surface of host endothelium. Previous studies have shown that 48 
parasite isolates from children with SM bind to several receptors, suggesting that synergistic 49 
effects between adhesion molecules may contribute to malaria pathophysiology. Yipp and 50 
others indicated that, in some cases, multiple receptors may be involved in adhesion, and 51 
recent data suggest that ICAM-1 and EPCR binding play a role in cerebral malaria [4-6]. The 52 
role of cytoadherence in SM, coupled with splenic evasion, suggests that a compound capable 53 
of reversing this adhesive phenotype would be desirable in terms of reducing clinical disease. 54 
Previous work has concentrated on inhibiting cytoadherence, whereas for actual cases of 55 
malaria it will be important that inhibitors of adhesion should also be able to reverse existing 56 
adhesion. 57 
It is preferable that antimalarial drug treatment is able to kill parasites in the non-58 
adhesive, ring stages to help prevent the next wave of pRBC from sequestrating and thus 59 
artemisinin is a good choice. This might explain the reduced mortality observed in field studies 60 
from Thailand (SEQUAMAT) [7] and Africa (AQUAMAT) [8] in which artemisinin and quinine 61 
(which kills exclusively mature pRBC) were compared. Despite this, there remains a high 62 
mortality rate accounting for in excess of 50% of deaths during the first 48 hours following 63 
hospital admission that is largely unaffected by the use of artemisinin-based combination 64 
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therapies (ACTs). This may be due to the pRBC already having been sequestered to the 65 
endothelium. Consequently, there is a need for adjunct therapies to support the critically ill 66 
patient, which can be used in combination with antimalarials such as artemisinin, to remove 67 
the sequestered pRBC mass or reduce its effects on the host, whilst conventional drugs kill 68 
the parasite effectively. 69 
Polysaccharides, which are found throughout both the animal and plant kingdoms, 70 
serve diverse functions in their tissues of origin and are frequently complex and heterogenous 71 
in structure. In plants, they include acidic polysaccharides, usually as a result of the presence 72 
of carboxylate groups (e.g. alginates and pectins) or O-sulfates groups (carrageenans), some 73 
of which tend to form gels, often dependent on their association with divalent cation(s). 74 
However, it is also possible to introduce other acidic groups (such as O-sulfates) by chemical 75 
means and these modified plant polysaccharides exhibit a range of biological activities in 76 
mammalian systems that arise from their ability to mimic the binding properties of the 77 
mammalian glycosaminoglycan (GAG) class of extracellular polysaccharides [9], which 78 
interact with many proteins.   79 
Modified, semi-synthetic polysaccharides are capable of binding distinct proteins with 80 
several levels of specificity. While highly acidic macromolecules could potentially interact in a 81 
non-specific and non-physiologically relevant manner with proteins, several highly negatively 82 
charged, sulfated polysaccharides, such as heparin (hep), heparan sulfate (HS), chondroitin 83 
sulfate (CS), dextran sulfate, fucoidan, as well as the non-sulfated glycosaminoglycan 84 
hyaluronic acid (HA), confer high affinity for particular proteins. Furthermore, anionic 85 
carbohydrates have been reported to inhibit erythrocyte invasion by Plasmodium merozoites, 86 
cytoadherence of pRBC to host cells, and to disrupt rosette formation between pRBC and 87 
uninfected erythrocytes [10]. 88 
Polysaccharides with different levels and patterns of sulfation have been demonstrated 89 
to inhibit P. falciparum growth and interfere with the adhesion of pRBC to the host endothelial 90 
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receptor CD36 [11-13]. Chemically O-sulfated cellulose was able to inhibit adhesion to CSA 91 
expressed on both CHO cells and placental tissue [14]. Cellulose sulfate (ca. 50 kDa), with 92 
significant levels of O-sulfate substitution at positions-2 (44 %) and -3 (36 %) of the glucose 93 
repeating units, showed the most favourable inhibitory capacity and was able to reverse bound 94 
pRBC to CHO cells and placental tissue [14]. In addition to being directly involved in adhesion, 95 
it has been reported that sulfated CSA is also able to inhibit and reverse adhesion of CSA-96 
adherent pRBC in vitro [14] and in splenectomised monkeys in vivo [15]. Furthermore, altering 97 
selected functional groups, especially sulfates on the saccharide branches, showed that it is 98 
possible to reduce binding, and in some cases augment the attachment of the pRBC to 99 
endothelium, all mediated by sulfated polysaccharides [16]. Other work using a modified 100 
derivative of heparin (sevuparin) has demonstrated the ability of modified glycosaminoglycans 101 
to inhibit cytoadherence and rosetting (the binding of infected erythrocytes to uninfected red 102 
blood cells) [17-19]).  103 
In this study, a variety of semi-synthetic, chemically modified polysaccharides with 104 
various levels and patterns of sulfation, derived from important industrial polysaccharides, 105 
were tested for their capacity to inhibit and reverse malaria cytoadherence, which may 106 
contribute to the development of novel therapeutics capable of targeting adhesion of pRBC to 107 
receptors such as ICAM-1 and CD36 on endothelial cells.     108 
 109 
  110 
  111 
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Materials & Methods 112 
Endothelial cells 113 
Primary human umbilical vein vascular endothelial cells (HUVEC) and human dermal 114 
microvascular endothelial cells (HDMEC) obtained from Promocell were cultured as per the 115 
manufacturer’s instructions. The Human Brain Endothelial Cell line (HBEC5i) was cultured as 116 
described by Tripathi et al. [5]. Primary endothelial cells at passage 4-6 were used for all 117 
experiments. Prior to use, cells were stimulated by addition of 1 ng.ml-1 TNF for 18 h to allow 118 
enhanced ICAM-1 expression on the surface of the endothelial cells. 119 
Parasite culture 120 
ItG (ITvar16) [20] and A4 (ITvar14) [21] laboratory parasite lines, which are well characterized 121 
for their binding to ICAM-1 and CD36 [22], were cultured under standard conditions in RPMI 122 
1640 medium supplemented with 37.5 mM HEPES, 7 mM D-Glucose, 25 ug.ml-1 gentamycin 123 
sulfate, 2 mM L-glutamine and 10% (v/v) pooled human serum at pH 7.2 in a gas mixture 124 
comprising 96% nitrogen, 3% carbon dioxide, and 1% oxygen. Additionally, recently culture 125 
adapted patient isolates: PO69, 8146 and 8026 were also included in the study [23]. 126 
Plasmagel trophozoite enrichment  127 
Parasite culture at trophozoite stage was centrifuged (500 g, 5 min) and the pRBC pellet was 128 
resuspended in a ratio of 2 volumes pellet to 3 volumes RPMI-based growth media without 129 
human serum (incomplete medium) and 5 volumes Plasmion (Laboratoire Fresenius Kabi, 130 
France), and allowed to settle for 20 - 30 min at 37 C. Trophozoite stage pRBC in the top layer 131 
were washed three times in incomplete medium and the parasitaemia assessed by Giemsa 132 
stained smear.   133 
 134 
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Selection of pRBC on ICAM-1 purified protein 135 
To increase the homogeneity of the ItG parasite population that expresses a PfEMP-1 136 
protein with high affinity for ICAM-1, the population was subjected to selection on ICAM-1 137 
protein. 2.5 µg of ICAM-1 protein was coated on to 50 µl of protein A Dynabeads (Invitrogen) 138 
in 200 µl of 1 % (v/v) Bovine Serum Albumin (BSA) in PBS and incubated for 1 hour at room 139 
temperature with gentle rotation (15 rpm). Dynabeads were washed with 1% BSA/PBS and  a 140 
magnetic stand . 50 µl of synchronized and enriched ItG parasite culture using Plasmion were 141 
incubated with the coated beads in 400 µl 1 % BSA/PBS for 45 min at room temperature by 142 
gentle rotation. Bound pRBC were washed 3 times with 1 % BSA/PBS using the magnetic 143 
stand. Beads were resuspended in 5 ml of complete RPMI media and transferred to culture in 144 
a T25 culture flask with the addition of 100 µl of washed red blood cells.  145 
Chemical sulfation of polysaccharides 146 
Carbohydrate precursors were O-sulfated by a modified version of the chlorosulfonic acid 147 
(CSA) sulphation method as described previously [9, 24]. Briefly, precursor carbohydrates 148 
were dissolved in ice-cooled dimethylsulfoxide with pyridine, before chlorosulfonic acid was 149 
added dropwise. The mixtures were held at 95 °C for 2 hr, cooled over ice and slowly 150 
neutralized with sodium hydroxide. Ethanol precipitations were performed prior to extensive 151 
dialyses (7 kDa cut-off membrane) against distilled water. Samples were lyophilized and stored 152 
at 4 °C prior to use. 153 
 154 
Static inhibition adhesion assay screening of the chemically 155 
modified, semi-synthetic anionic polysaccharides on 156 
endothelial cells 157 
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Initially, solutions of 44 chemically-modified semi-synthetic anionic polysaccharides 158 
(see Supplementary Data) were diluted to 1 mg.ml-1 in binding buffer (RPMI 1640 with 25 mM 159 
HEPES, 11 mM D-Glucose, 2 mM L-glutamine pH 7.2) and screened for their anti-adhesive 160 
properties using a static cell binding based assay as described by [22]. HUVEC, (2-6th 161 
passage) were seeded onto 1% w/v gelatin coated 13 mm Thermanox coverslips (Nunc). Once 162 
confluent, the cells were incubated overnight at 37 °C with 1 ng.ml-1 TNF (Biosource 163 
International). Cells were then washed with binding buffer prior to use. A suspension of 3% 164 
pRBC and 1% HCT containing 1 mg.ml-1 of compound was allowed to bind, for 1 hour with 165 
mixing every 10 minutes, and following two dip washes, coverslips were placed in a gravity 166 
wash for 30 min. Coverslips were then transferred to a second gravity wash for 10 min,  fixed 167 
in 1% v/v glutaraldehyde and stained with Giemsa. Control experiments lacking the addition of 168 
the test compounds were also included. Coverslips were dried and mounted on slides using 169 
DPX mountant (Sigma). Levels of adhesion were quantified by microscopy under 300x 170 
magnification. The number of adherent pRBC per mm2 was calculated. 171 
 172 
Flow adhesion assay inhibition by the chemically modified, 173 
semi-synthetic anionic polysaccharides on endothelial cells 174 
This type of assay attempts to mimic the conditions seen in the post capillary venule by 175 
allowing pRBC to flow over slides coated with endothelial cells. Permanox chamber slides 176 
(Nunc) were coated with 1% (w/v) gelatin for 1 hr at 37 °C, seeded with endothelial cells 177 
(HUVEC; HDMEC; HBEC5i) and incubated until confluent. Confluent slides were then 178 
incubated overnight at 37 C with 1 ng.ml-1 TNF prior to use.  PRBC suspensions (3% 179 
parasitaemia and 1% HCT) with or without 1 mg.ml-1 modified polysaccharides were flowed 180 
over the endothelial cells for 5 min, followed by binding buffer (without the compounds) for 2 181 
min to remove unbound cells. The flow rate yielded a wall shear stress of 0.05 Pa, used widely 182 
to mimic wall shear stresses in the microvasculature. The number of adherent pRBC was 183 
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counted in six separate fields under 300x magnification and the density of parasitized red blood 184 
cells per unit area (pRBC.mm-2) was calculated. All assays were carried out at 37 C and were 185 
performed in duplicate or triplicate on three independent occasions. 186 
Flow adhesion assay reversal by the chemically modified, 187 
semi-synthetic anionic polysaccharides on endothelial cells 188 
Reversal cell assays were carried out using a similar procedure to the flow inhibition adhesion 189 
cell assay but with an initial phase in the absence of compounds.  PRBC at 3% parasitaemia 190 
and 1% HCT were flowed through the slide for 5 min to allow for pRBC adhesion. Flow was 191 
continuous throughout the experiment at 0.05 Pa shear stress. Binding buffer was used to 192 
remove unbound pRBC. Timing was started at the beginning of this wash, which continued for 193 
2 min before the binding medium was swapped for medium containing the modified compound 194 
being tested. The number of bound cells in six fields along the slide was counted at 0, 5, 10, 195 
15 and 20 min. The number of adherent cells counted was used to calculate the pRBC bound 196 
per mm2.  197 
 198 
Prothrombin time (PT) coagulation assay 199 
Samples, controls and Thromborel S reagent (Siemens) were pre-warmed to 37 C prior to use. 200 
Serially diluted, sulphated carbohydrate samples (50 μl) were incubated with normal human 201 
citrated plasma (50 μl) for 1 min at 37 C prior to the addition of Thromborel S reagent (50 μl). 202 
The time taken for clot formations to occur (an upper maximal of 2 min was observed) were 203 
recorded using a Thrombotrak Solo coagulometer as per the manufacturer’s instructions. 204 
Water and sodium porcine mucosal heparin (203 IU/mg) were assayed as controls The EC50 205 
values of all semi-synthetic, sulphated carbohydrates were determined using a sigmoidal dose 206 
response curved fitted post normalisation (with a 100% upper maximal at 2 mins; 0% lower 207 
maximal represented by the time required for the water control to clot normal human citrated 208 
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plasma) with GraphPad Prism 6 software and compared to those obtained for the heparin 209 
control. 210 
Activated partial thromboplastin time (aPTT) coagulation 211 
assay 212 
Serially diluted, sulphated carbohydrate samples (25 μl) were incubated with normal human 213 
citrated plasma (50 μl; NHSBT) and Pathromtin SL reagent (50 μl; Siemens) for 2 min at 37 C 214 
prior to the addition of calcium chloride (25 μl; 50 mM). The time taken for clot formations to 215 
occur (an upper maximal of 2 mins was observed) were recorded using a Thrombotrak Solo 216 
coagulometer (Axis-Shield) as per the manufacturer’s instructions. Water and sodium porcine 217 
mucosal heparin (203 IU/mg; VWR) were assayed as controls. The EC50 values of all semi-218 
synthetic, sulphated carbohydrates were determined using a sigmoidal dose response curved 219 
fitted post normalisation (with a 100% upper maximal at 2 mins; 0% lower maximal represented 220 
by the time required for the water control to clot normal human citrated plasma) with GraphPad 221 
Prism 6 software and compared to those obtained for the heparin control. 222 
MTT cell proliferation assay 223 
Potential toxic effects of sulphated carbohydrates on endothelial cells were screened against 224 
utilising the tetrazolium salt, 3-4,5 dimethylthiazol-2,5 diphenyl tetrazolium bromide (MTT) 225 
proliferation assay. Briefly, a serial dilution of the test carbohydrate was prepared and added 226 
to HUVEC cells (2×104 cells) in a multiwell plate (Greiner); a positive control, the Golgi disruptor 227 
brefeldin A (10 μl, 10 ng.ml-1 in PBS), and PBS (10 μl, as a negative control) were also included. 228 
Post 48 hr incubation, MTT solution (10 μl, 0.5% w/v in PBS) was added to all wells for 4 hr at 229 
37 C. Finally, the supernatants were discarded, the cells washed (PBS) and treated with 230 
dimethylsulfoxide (10 μl). Cell proliferation levels were ascertained indirectly by 231 
spectrophotometry at a λabs of 540 nm. 232 
 233 
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Statistical analyses 234 
Results shown are the mean of two independent experiments ± Standard Deviation (SD). A 235 
standard unpaired t-test was performed (Figs 1,2 and 3), ANOVA (Kruskal Wallis with post-236 
test) (Fig 4)  and unpaired t-test (Fig 5) using GraphPad Instat3 software and considered 237 
significant when P<0.05. 238 
 239 
Chemical characterisation methods for GSII are presented as supplementary information in S1 240 
File.  241 
  242 
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Results 243 
Both static and flow based assays were used for this work, partly to allow comparison with 244 
other studies, which usually rely on static assays, but also to demonstrate the variation that 245 
can be observed in these two different formats.   246 
Inhibition of pRBC binding to endothelial cells by chemically 247 
modified, semi-synthetic anionic polysaccharides 248 
A number of chemically modified, semi-synthetic anionic polysaccharides were 249 
screened for their anti-adhesion properties with a static based endothelial cell-binding assay 250 
against two well-characterised parasite lines, ItG and A4, for their binding to TNF-activated 251 
human primary endothelial cells HUVEC (human umbilical vein endothelial cells – large vessel 252 
endothelium) and HDMEC (human dernal microvascular endothelial cells). TNF activation was 253 
used to mimic the pro-inflammatory environment in a human host during malaria infection, and 254 
upregulates the expression of a number of cytoadherence receptors.  One of the key 255 
differences between HUVEC and HDMEC, is that the latter expresses CD36, but HUVEC does 256 
not (or at very low levels that do not support CD36-based adhesion). Of the 44 compounds 257 
screened in a cell-based static assay (S1 Table ; S1 Fig), 10 showed potential adhesion 258 
inhibition by producing 50% reduction in binding compared to the control receiving no 259 
treatment (Table 1). From the flow-based screening we identified only two 260 
compounds:glycogen type 2 sulfate from Oyster (MS34, GSII) and phenoxyacetylcellulose 261 
sulfate (MS40, PACS)) that showed a significant adhesion inhibitory effect; they reduced the 262 
binding of the A4 strain up to 70% and achieved 10-40% reduction in binding of the ItG strain 263 
to TNF activated HDMEC in comparison to the un-treated control (S2 Fig). 264 
 265 
Table 1 – Compounds identified in primary screen. 266 
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Compound Description Carbohydrate composition 
1 Glycogen sulfate (type II) (GS) α(1→4), α(1→6), polyglucan 
2 Phenoxyacetyl cellulose sulfate (PACS) β(1→4) phenoxyacetylated polyglucan 
3 Ethyl cellulose sulfate β(1→4) acetylated polyglucan 
4 Gum Arabic sulfate β(1→3), β(1→3) polygalactan core 
5 Starch sulfate α(1→4) polyglucan 
6 Poly-D-methylgalacturonic acid sulfate α(1→4) methylated polygalacturonic acid 
7 Poly-D-galacturonic acid sulfate α(1→4) polygalacturonic acid 
8 Tragacanth sulfate α(1→4) polygalacturonic acid, β(1→3) xylan 
9 Hydroxypropyl methyl cellulose sulfate β(1→4) hydroxpropylated polyglucan 
10 Paramylon sulfate β(1→3) polyglucan 
 267 
 268 
 269 
Reversal effect of chemically modified, semi-synthetic 270 
anionic polysaccharides on endothelial cells 271 
Having identified GSII and PACS as capable of inhibiting parasite adhesion, we further 272 
screened these compounds in terms of their ability to reverse the binding of two-laboratory 273 
parasite strains ItG (Fig 1) and A4 (Fig 2) to distinct endothelial cell lines (HUVEC, HDMEC 274 
and HBEC5i) using a cell-based flow adhesion assay. HBEC5i is an immortalised human brain 275 
microvascular cell line with a similar profile of receptor expression to HUVEC.  For this 276 
secondary screen, the comparisons for inhibitory effects were made to the situation at 0 min, 277 
but it is known that there is a low-level loss of binding of PRBC during flow adhesion assays, 278 
and this was incorporated into later experiments by running a ‘no compound/ PBS’ control for 279 
the same period.  GSII disrupted binding with 40% to 60% reduction of pRBC on all these cell 280 
types, comparing 0 min with 20 min exposure to the compounds (Figs 1A and 2A), whereas 281 
PACS showed smaller, variably  significant reversal effects across all the endothelial cells (Figs 282 
1B and 2B) (Table 2).  283 
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Table 2 - p-values for cytoadherence assays: (unpaired t-test: Figs 1 and 2).  Comparison 284 
is between t=20 min and t=0 min and not a ‘no compound’ control at 20 min. 285 
 ItG A4 
 GSII PACS GSII PACS 
HUVEC 0.0079 0.0611 0.0037 0.018 
HDMEC 0.0128 0.2326 0.0053 0.024 
HBEC5i 0.002 0.0668 0.0098 0.0661 
 286 
 287 
Fig 1: Reversal of ItG pRBC binding to different TNF-stimulated endothelial cells (HUVEC, 288 
HDMEC and HBEC5i) by 1 mg.ml-1 of (A) GSII and (B) PACS for 20 mins under flow conditions. 289 
pRBC bound were calculated every 5 mins and expressed as a percentage (%) bound 290 
pRBC.mm-2 compared to 0 min time point.  Data for Figs 1 and 2 are provided in supporting 291 
information in S1 and S2 Data. 292 
Fig 2: Reversal effect on A4 pRBC binding to different TNF-stimulated endothelial cells 293 
(HUVEC, HDMEC and HBEC) after flowing through 1mg.ml-1 of (A) GSII and (B) PACS for 20 294 
mins under flow conditions. pRBC bound were calculated every 5 mins and expressed as a 295 
percentage (%) bound pRBC.mm-2 compared to 0 min time point.  Data for Fig 2 are provided 296 
in supporting information in S2 Data. 297 
 298 
Reversal effect of GSII and PACS on other parasite isolates 299 
To examine the effect of both GSII and PACS using a broader range of parasite 300 
variants, three recently laboratory-adapted, ICAM-1-selected patient isolates (P069, 8146 and 301 
8026) were used in addition to ItG [23]. Initially the ability of the compounds to disrupt pRBC 302 
already bound to ICAM-1 protein under flow conditions was tested. The reversal was similar 303 
for each parasite isolate, albeit with some variation, and around 20-30% pRBC were removed 304 
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with GSII being more effective than PACS (Fig 3 and Table 3), but only P069/ GSII was 305 
statistically significant. The reduction in binding was significant when using TNF activated 306 
HUVEC cells with a 40-50% reduction under static conditions that was significant with GSII 307 
(Fig 4 and Table 4), but lower and variably significant with PACS.   Under flow conditions, GSII 308 
showed consistent reductions in binding of all isolates tested again reaching significant or near 309 
significant levels, unlike PACS, which showed no significant reductions in binding when 310 
compared to ‘no-compound’ control (Fig 5 and Table 5).  311 
Table 3 - p-values for cytoadherence assays: (unpaired t-test: Fig 3). Comparison is 312 
between control (no compound) at 20 min with the relevant compound treatment at 20 min. 313 
 ItG P069 8146 8026 
GSII 0.1094 0.0134 0.1328 0.0702 
PACS 0.224 0.7762 0.4295 0.9271 
 314 
Table 4 - p-values for cytoadherence assays: (ANOVA-Kruskal-Wallis: Fig 4). 315 
Comparison is with the relevant control for each isolate.  316 
 ItG P069 8146 8026 
GSII < 0.001 < 0.01 < 0.001 < 0.001 
PACS < 0.05 > 0.05 > 0.05 < 0.01 
 317 
Table 5 - p-values for cytoadherence assays: (unpaired t-test: Fig 5). Comparison is 318 
between control (no compound) at 20 min with the relevant compound treatment at 20 min. 319 
 ItG P069 8146 8026 
GSII 0.0418 0.0522 0.0673 0.0361 
PACS 0.171 0.2095 0.407 0.5997 
 320 
 321 
Fig 3: Reversal effect of 1 mg.ml-1 GSII and PACS on binding of lab-adapted patient isolates 322 
A) ItG; B) P069; C) 8146; D) 8026 to ICAM-1 under flow conditions. pRBC bound were 323 
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calculated for every 5 mins and expressed as percentage (%) bound pRBC.mm-2 compared to 324 
0 mins. Control is no compound (PBS only). X-axis is time in minutes after addition of GSII, 325 
PACS or PBS.  Data for Fig 3 are provided in supporting information in S3 Data. 326 
Fig 4: Reversal effect of 1 mg.ml-1 GSII and PACS on binding to HUVEC using lab-adapted 327 
patient isolates (P069, 8146 and 8026) under static assay conditions, with ItG used for 328 
comparison. The remaining bound pRBC were counted and expressed as bound pRBC.mm-2 329 
mean ± standard deviation. Control is no compound (PBS only). Data for Fig 4 are provided in 330 
supporting information in S4 Data. 331 
Fig 5: Testing 1 mg.ml-1 GSII and PACS for their ability to reverse existing binding under flow 332 
conditions. A) ItG; B) P069; C) 8146; D) 8026 reversal of binding on TNF-activated HUVEC. 333 
pRBC bound were determined every 5 minutes and expressed as percentage (%) bound 334 
pRBC. mm-2 compared to 0 mins. Control is no compound (PBS only).  X-axis is time in minutes 335 
after addition of GSII, PACS or PBS. Data for Fig 5 are provided in supporting information in 336 
S5 Data. 337 
 338 
Anticoagulant potential of GSII  339 
In light of the reversal efficacy of GSII, the ability of this sulfated carbohydrate to perturb 340 
coagulation within pooled human plasma was determined. The prothrombin time (PT) and 341 
activated partial thromboplastin time (aPTT) were measured for GSII, thereby determining the 342 
overall effect on the extrinsic and intrinsic coagulation pathways respectively (both assays also 343 
include the common coagulation pathway). The sulfated carbohydrate porcine mucosal 344 
heparin (sodium), an approved clinical anticoagulant of known activity (201 IU.mg-1) was 345 
employed for comparison as a relevant control. The anticoagulant potential of GSII is highly 346 
attenuated when compared to that of the sodium heparin control, in both the PT (EC50 of 5.44 347 
x 104 µg.mL-1 versusEC50 of 2.7 x 10-1 , respectively; Fig 6A) and aPTT (EC50 of 1.53 x 104 348 
versus 6.74 x 10-1 µg.mL-1, respectively; Fig 6B) coagulation assays.  349 
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 350 
Fig 6: A) Prothrombin time (PT) assay to determine EC50 for the compounds for coagulation. 351 
100% represents the inhibition of clotting, determined as a PT of >120 seconds, 0% represents 352 
a normal PT clotting time for pooled human plasma (≈ 13 - 14 seconds). EC50 Porcine Mucosal 353 
Heparin (PMH, the clinically used antihrombotic agent) = 2.74 x 10-1 µg.mL-1; EC50 GSII = 5.44 354 
x 104µg.mL-1. B) Activated partial thromboplastin time (aPTT) assay. 100% represents the 355 
inhibition of clotting, determined as a aPTT of >120 seconds, 0% represents a normal PT 356 
clotting time for pooled human plasma (≈ 35 seconds). EC50 Porcine Mucosal Heparin (PMH) 357 
= 6.74 x 10-1 µg.mL-1; EC50 PACS = 1.53 x 104 µg.mL-1. Data for Fig 6 are provided in supporting 358 
information in S6 Data. 359 
 360 
Potential cytotoxicity of GSII  361 
Potential cytotoxic effects of GSII were screened for using the widely adopted MTT 362 
assay, which detects the chromogenic change that occurs upon the mitochondrial reduction 363 
of the tetrazol dye MTT to yield formazan in living cells. This reduction does not occur in 364 
deceased cells, thereby acting as an indirect measure of toxicity, through the reduced levels 365 
of cell proliferation that would be observed when a cytotoxic agent is present, compared to 366 
that of the normally proliferating cell population. The incubation of HUVEC endothelial cells in 367 
the presence of GSII at increasing concentrations up to 10 mg.mL-1 showed no apparent 368 
evidence of cytotoxicity when compared to the PBS control (Fig 7).  369 
 370 
Fig 7: Cell viability measured indirectly using the MTT cell proliferation assay after 371 
incubation for 48 hours with varying concentrations of GSII on HUVEC cells. All results are 372 
expressed as a percentage relative to a non-toxic control (PBS). Brefeldin A (a known Golgi 373 
disruptor) at 10 ng.ml-1 was used as a toxicity control (data not shown). The data plotted is 374 
the mean ±S.D. of triplicate values.  Statistical analysis was performed using an unpaired t-375 
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test. All concentrations of GSII assayed were statistically insignificant from the PBS control 376 
(i.e. P > 0.05). Data for Fig 7 are provided in supporting information in S7 Data.  377 
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Discussion 378 
Erythrocytes infected with P. falciparum can bind to endothelial receptors, leading, in part, to 379 
the clinical manifestations associated with SM. Consequently, molecules that can inhibit or 380 
interrupt these interactions may have a role in improving understanding of host-parasite 381 
biology, as well as in developing new therapies for severe disease. Highly sulfated 382 
polysaccharides not only inhibit binding of pRBC to CSA [12-14], but can also reverse pRBC 383 
adhesion in the placenta during pregnancy [25, 26].  Interactions between pRBC and host cell 384 
membranes involve multiple interactions between several distinct ligands and receptors. The 385 
cell surface receptors, including ICAM-1, CD36, EPCR, complement receptor 1 and 386 
chondroitin sulfate-A, bind to different regions of the PfEMP-1 protein (the cysteine rich inter-387 
domain region (CIDR) and Duffy binding-like domains (DBL) [27, 28]. The extent of 388 
involvement of these receptors varies between parasite variants and may correspond to 389 
pathology [29]. For example, chondroitin sulfate A (repeating -4 GlcA β(1-3) GalNAc4S β(1- 390 
disaccharide units) is implicated in placental malaria [25].  391 
  392 
 The interactions between pRBCs and host cells almost certainly involve manifold 393 
protein-carbohydrate contacts across the interacting surfaces, in addition to HS. These lead to 394 
strong interactions between cells that can be much more difficult to dislodge than the simple 395 
sum of the individual components. This multi- or polyvalent effect is why small molecules are 396 
unable to reverse binding interactions at reasonable concentrations. In contrast, if larger 397 
molecules are employed, then effective inhibition becomes possible as long as the appropriate 398 
geometric and stereochemical requirements to make effective bonds with receptors are 399 
present [30].  400 
Receptor-ligand binding is a dynamic process and this is especially relevant in the case 401 
of multivalent interactions. In cell-to-cell interactions, multivalency exists at two distinct levels. 402 
In the first, there is multivalency across the surface of the interacting cells, formed by many 403 
individual molecular contacts. In the second, at the more detailed molecular level, there are 404 
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multiple bonds formed between individual interacting molecules, e.g. carbohydrate-protein or 405 
protein-protein, which could comprise, for example, hydrogen bonds at several locations. The 406 
dynamic aspects of both situations are essentially similar in nature, while being very different 407 
in scale. Polyvalent interactions can be viewed as a series of discrete interactions, spread out 408 
in space, but dynamic in nature and in a constant state of change. Each interacting pair spends 409 
some time bound and some unbound, but this lacks overall synchronisation. A small molecule 410 
inhibitor can only bind one, or a few, of the available binding sites as and when they become 411 
available, but cannot achieve efficient competition because, without resorting to extremely high 412 
concentrations, it can never occupy sufficient sites locally to dislodge the original binding 413 
molecules. If, on the other hand, a larger inhibitor with the appropriate spatial and 414 
stereochemical characteristics to enable it to make first one, two and then several interactions 415 
is introduced, then this can effectively compete with the ligand-receptor system and eventually 416 
dislodge the original binding partners to replace one of them with itself. Such effective 417 
competition can only be achieved by larger molecules, including polysaccharides. 418 
The inhibitory interactions described here are not simply charge-driven. There is an 419 
element of complementarity, supported by studies showing that low-sulfated structures can 420 
inhibit pRBC binding [16]. GSII must possess specific dimensions and stereochemical 421 
characteristics that enable it to act as an effective multivalent inhibitor at the level of both 422 
molecular and cellular interactions. This requirement for particular geometric and charge 423 
distribution is seen in that simply increasing charge does not necessarily improve inhibition 424 
[see compound 36, supplementary data]. Additionally, polysaccharide inhibitors are not 425 
necessarily acting only via a single type of ligand – receptor interaction, so polysaccharide 426 
heterogeneity may be an advantage.  427 
Ten potential inhibitory polysaccharides were identified (Table 1) from a library of 44 428 
modified semi-synthetic anionic polysaccharides using a simple static binding assay. These 429 
exhibited significant inhibition with two lab-adapted P. falciparum lines, A4 and ItG under static 430 
conditions (S1 Fig). We then used the more complex, but physiologically relevant, flow-based 431 
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binding assay to investigate the ability of the ten polysaccharides to inhibit binding of these two 432 
laboratory-adapted strains. GSII and PACS gave approximately 60-70% reduction in binding 433 
when using A4, but not ItG (S2 Fig). The interaction between pRBC and endothelial cells varies 434 
with the composition of the variant surface protein expressed on the different pRBC lines and 435 
the repertoire of endothelial receptors on the host cells. Comparing binding efficiencies is 436 
complicated by the different assay platforms used, however, under static conditions ItG 437 
supports higher binding to ICAM-1 and CD36 than A4, which is also seen under static 438 
conditions for HUVEC and HDMEC [22]. Under flow conditions, binding to endothelial cells for 439 
these two parasite lines is different; A4 showing higher binding to TNF-induced HUVEC and 440 
both lines showing essentially equivalent levels of binding to HDMEC.  Therefore, the variability 441 
seen in the level of inhibition between the different parasite lines may be due to differential 442 
inhibition of a range of interactions, and no preference for any specific host receptor can be 443 
discerned. This is un-surprising since the polysaccharide library was not designed to target 444 
specific host-parasite interactions for cytoadherence. 445 
Polysaccharides such as dextran sulfate and fucoidan can inhibit adhesion of P. 446 
falciparum to host receptors such as CSA and CD36 [12-14] and regioselectively modified 447 
polysaccharides, including modified carrageenans inhibit binding of pRBC to CD36 [31, 32], 448 
as well as modified heparin structures [18]. GSII can now be added to this list but, the greater 449 
challenge related to whether GSII or PACS could reverse bound pRBC, which is the situation 450 
found clinically in SM. To answer this, three different EC (HUVEC, HDMEC and HBEC5i) were 451 
used in combination with A4 and ItG to provide a further screen for activity prior to more 452 
detailed analysis. Brain EC is potentially important as it may indicate whether GSII and PACS 453 
could reduce sequestration in this tissue, as detected in cerebral malaria. 454 
GSII gave a better response than PACS on different EC (HUVEC, HDMEC and 455 
HBEC5i) and was more effective in reversal of A4 binding to HUVEC and HDMEC cells 456 
compared to human brain microvascular endothelial cells (HBMEC). PACS did not show any 457 
ability to reverse binding with ItG but gave slightly better results on reversing A4 binding to 458 
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HDMEC and HUVEC. Although GSII and PACS showed different effects on reversing 459 
adhesion of both lab-adapted strains, neither had a significant effect on HBEC5i, which is a 460 
concern in terms of developing either compound as an adjunct therapy for CM. However, the 461 
HBEC5i used here is an immortalized rather than a primary cell line and this may have 462 
influenced the level of binding and inhibition. Differential binding of parasite lines to HBEC5i 463 
and primary HBMEC has been reported  [33]. Further work on primary brain endothelium and 464 
tissue sections will be needed, as will understanding the impact of releasing many rigid pRBC 465 
into the circulation on the health of the patient.  466 
GSII and PACS were further investigated by testing a panel of recently laboratory-467 
adapted parasite isolates (8146, 8026 and P069). Isolate 8146 is a strong ICAM-1 binder, with 468 
8206 and P069 showing slightly lower levels of adhesion to this receptor [23]. Each parasite 469 
strain showed roughly equivalent reversal responses under static and flow conditions, with up 470 
to 80% reduction under flow (Figs 4 and 5) suggesting that GSII could have broad application 471 
in terms of pRBC binding inhibition. GSII contains low sulfate (and charge) and the results 472 
support the work of McCormick et al., who showed that low sulfated glycoconjugates were able 473 
to modulate binding of pRBC to different receptors [16].   474 
Significant anticoagulant activity is a well-known off-target effect that has previously 475 
hampered the application of some, but not all, sulphated molecules as potential therapeutic 476 
agents. The PT and aPTT coagulation times of GSII suggest that it possesses negligible 477 
anticoagulant potency (10-6) compared to pharmaceutical heparin. Furthermore, GSII does not 478 
significantly perturb endothelial cell proliferation by tetrazolium based dye, MTT, suggesting 479 
that it possesses favourable bioactivity, is minimally anticoagulant and non-toxic.   480 
This work has demonstrated the potential of chemically modified, semi-synthetic 481 
anionic polysaccharides to both inhibit and reverse cytoadherence in malaria and offers 482 
potential for the future development of pharmaceutical agents based on these materials.  483 
 484 
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Supporting Information 616 
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S1 Fig. Screening compounds under static assay conditions. Binding response of ItG 617 
(top) and  A4 (bottom) to modified polysaccharide compound at 1 mg/ml on TNF-stimulated 618 
HUVEC and HDMEC under static condition (single screening). pRBC binding (3%, 619 
parasitemia; 1% HCT) observed after polysaccharide treatment for one hour. The remaining 620 
bound pRBC after gravity wash were counted and expressed as % bound pRBC/ mm2 (N=1) 621 
compared to control, without polysaccharide. 622 
 623 
S2 Fig. Screening compounds under flow assay conditions.Binding response of ItG and 624 
A4 to modified polysaccharides compounds at 1 mg/ml on TNF-stimulated HDMEC under 625 
flow conditions. The remaining bound parasites after 20 mins wash was counted and 626 
expressed as % bound pRBC/ mm2 ± standard deviation compared to control without 627 
polysaccharide. ND; not done. MS34 (ItG and A4) & MS40 (A4), P < 0.05 (compared to 628 
control). 629 
 630 
S3 Fig. Characterisation of GSII. 1H NMR spectrum of GSII at 400 MHz, with 128 scans, 2s 631 
delay. Inset - Comparison of 1H NMR spectra of GSII and its unsulfated precursor, glycogen 632 
type II.  This is provided as background information and is not cited in the paper. 633 
 634 
 635 
S1 Table. Sulfated carbohydrates assayed. A list of all the compounds screened in this 636 
paper. 637 
S1 File. Supplementary methods. Description of methods associated with chemical 638 
characterisation of GSII. 639 
S1 and Data: Primary data supporting Fig 1.  640 
S2 Data: Primary data supporting Figs 1 and 2. 641 
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S3 Data: Primary data supporting Fig 3. 642 
S4 Data: Primary data supporting Fig 4. 643 
S5 Data: Primary data supporting Fig 5. 644 
S6 Data: Primary data supporting Fig 6. 645 
S7 Data: Primary data supporting Fig 7. 646 
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